PTC Therapeutics, Inc. (PTCT) Earnings History
Annual and quarterly earnings data from 2011 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | 50.1% | 39.4% |
| 2024 | 92.9% | -37.5% | -45.0% |
| 2023 | 93.0% | -46.9% | -66.8% |
| 2022 | 93.6% | -64.0% | -80.0% |
| 2021 | 94.0% | -69.5% | -97.3% |
Download Data
Export PTCT earnings history in CSV or JSON format
Free sign-in required to download data
PTC Therapeutics, Inc. (PTCT) Earnings Overview
As of February 28, 2026, PTC Therapeutics, Inc. (PTCT) reported trailing twelve-month net income of $752M, reflecting +2.6% year-over-year growth. The company earned $8.63 per diluted share over the past four quarters, with a net profit margin of 0.4%.
Looking at the long-term picture, PTCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $683M in fiscal 2025, representing a new all-time high.
PTC Therapeutics, Inc. maintains positive profitability with, operating margin of 0.5%, and net margin of 0.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), PTCT has outperformed on profitability metrics. Compare PTCT vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $683M | +287.9% | $867M | $7.78 | 39.4% | 50.1% |
| 2024 | -$363M | +42.0% | -$303M | $-4.73 | -45.0% | -37.5% |
| 2023 | -$627M | -12.1% | -$440M | $-8.37 | -66.8% | -46.9% |
| 2022 | -$559M | -6.7% | -$447M | $-7.79 | -80.0% | -64.0% |
| 2021 | -$524M | -19.6% | -$374M | $-7.43 | -97.3% | -69.5% |
| 2020 | -$438M | -74.2% | -$432M | $-6.64 | -115.1% | -113.4% |
| 2019 | -$252M | -96.4% | -$241M | $-4.27 | -82.0% | -78.6% |
| 2018 | -$128M | -62.1% | -$116M | $-2.75 | -48.4% | -43.7% |
| 2017 | -$79M | +44.4% | -$64M | $-2.02 | -40.6% | -33.1% |
| 2016 | -$142M | +16.6% | -$132M | $-4.17 | -171.8% | -159.7% |
See PTCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTCT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare PTCT vs AGIO
See how PTCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is PTCT growing earnings?
PTCT EPS of $8.63 reflects slowing growth at +2.6%, below the 5-year CAGR of N/A. TTM net income is $752M. Expansion rate has moderated.
What are PTCT's profit margins?
PTC Therapeutics, Inc. net margin is +0.4%, with operating margin at +0.5%. Below-average margins reflect competitive or cost pressures.
How consistent are PTCT's earnings?
PTCT earnings data spans 2011-2025. The current earnings trend is +2.6% YoY. Historical data enables comparison across business cycles.